- Design
- Phase 2 part of a randomised, double-blind, placebo-controlled phase 2/3 trial
- Population
- Adults with cutaneous lupus erythematosus
- Primary outcome
- CLA-IGA-R erythema score 0–1 at week 16
- Effect
- 14.7% vs 2.9% (p=0.026); CLASI-70 at week 24 21.7% vs 5.8%
AMETHYST Part A is the phase 2 stage of a randomised, double-blind, placebo-controlled phase 2/3 study of litifilimab, a monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells, in cutaneous lupus erythematosus. Participants received litifilimab 225 mg or placebo every four weeks for 24 weeks.
At week 16, 14.7% on litifilimab reached a clear or almost clear erythema score (CLA-IGA-R 0–1) versus 2.9% on placebo (p=0.026). At week 24, CLASI-70 responses were 21.7% versus 5.8% (p=0.020). The drug was generally well tolerated, consistent with earlier studies.
Cutaneous lupus has no approved targeted therapy, so a drug acting on the interferon-producing cells that drive it is worth following. But response rates are low in absolute terms: about six in seven treated patients did not reach clear or almost clear skin at week 16. The secondary endpoints were not powered for significance. Hydroxychloroquine, photoprotection and topical treatment remain the foundation, and litifilimab is not approved anywhere.
- Continue to use hydroxychloroquine, photoprotection and topical or intralesional steroids as first-line treatment for cutaneous lupus.
- Expect modest absolute response rates if litifilimab reaches the clinic; most patients in this trial did not clear.
- Consider trial referral for patients with refractory cutaneous lupus where available.
- Screen patients with cutaneous lupus for systemic disease at diagnosis and at intervals.
Why it matters
It is one of the first targeted drugs to show a controlled benefit in a skin disease that has relied on antimalarials and steroids for decades.
Don't overread it
This is phase 2 evidence with modest response rates, not a reason to change current treatment.
The statistics, in plain English
The primary endpoint was met, with about 12 percentage points more patients reaching clear or almost clear skin. The p-values near 0.02 to 0.03 indicate a real but not overwhelming signal in a phase 2 trial. The secondary results were not powered, so they support rather than confirm the primary finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free